16α-[<sup>18</sup>F]Fluoro-17β-Estradiol Positron Emission Tomography to Measure Regional Estrogen Receptor Expression in Breast Cancer
Authors: David A. Mankoff, Amy S. Clark, Christine E. Edmonds, Sophia R. O'Brien, Austin R. Pantel
Journal: Journal of Clinical Oncology (2022)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer. May 18, 2022 ARTICLE CITATION DOI: 10.1200/JCO.22.01055 Journal of Clinical Oncology - published online before print August 30, 2022 PMID: 36041088 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography to Measure Regional Estrogen Receptor Expression in Breast Cancer David A. Mankoff , MD, PhD1,2xDavid A. MankoffSearch for articles by this author; Amy S. Clark, MS, MSCE2,3xAmy S. ClarkSearch for articles by this author; Christine E. Edmonds , MD1xChristine E. EdmondsSearch for articles by this author; Sophia R. O'Brien , MD1xSophia R. O'BrienSearch for articles by this author; and Austin R. Pantel, MD, MSTR1xAustin R. PantelSearch for articles by this author Show More 1Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA2Breast Cancer Research Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA3Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA https://doi.org/10.1200/JCO.22.01055 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologySUPPORTSupported in part by NCI Cancer Center Support Grant, P30CA016520.AUTHOR CONTRIBUTIONSConception and design: David A. Mankoff, Amy S. Clark, Austin R. PantelCollection and assembly of data: Christine E. Edmonds, Sophia R. O'Brien, Austin R. PantelManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography to Measure Regional Estrogen Receptor Expression in Breast CancerThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).David A. MankoffEmployment: Trevarx Biomedical (I)Stock and Other Ownership Interests: Reflexion Medical, ImaginAb, Trevarx BiomedicalConsulting or Advisory Role: Philips Healthcare, GE HealthcarePatents, Royalties, Other Intellectual Property: Trevarx has license to radiopharmaceuticals (I)Other Relationship: Reflexion Medical, ImaginAb, Trevarx BiomedicalAmy S. ClarkHonoraria: SiemensConsulting or Advisory Role: NovartisResearch Funding: Novartis (Inst), Seattle Genetics (Inst), Lilly (Inst)Christine E. EdmondsStock and Other Ownership Interests: Moderna TherapeuticsAustin R. PantelConsulting or Advisory Role: GE Healthcare, Blue Earth Diagnostics, ProgenicsResearch Funding: Progenics (Inst)Travel, Accommodations, Expenses: GE Healthcare, Blue Earth DiagnosticsNo other potential conflicts of interest were reported. Companion Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer